Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medi-radiopharma	TECHNETIUM TC99M MERTIATIDE KIT	technetium tc-99m mertiatide kit	INJECTABLE;INJECTION	206489-001	Feb 6, 2020	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sun Pharm Inds Inc	TECHNETIUM TC99M MERTIATIDE KIT	technetium tc-99m mertiatide kit	INJECTABLE;INJECTION	208994-001	Jul 12, 2019	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 24, 2026

Technetium Tc 99m mertiatide kit is a mature, off-patent diagnostic radiopharmaceutical used primarily for renal imaging and diuretic renography. Its commercial value comes from recurring hospital demand, rapid clinical workflow, and limited substitutability in patients with reduced renal function. The market has low patent risk and limited product-level revenue transparency. Financial performance is driven more by nuclear-medicine procedure volume, technetium-99m availability, reimbursement, manufacturing reliability, and hospital purchasing contracts than by exclusivity.

Technetium Tc 99m Mertiatide Kit Market Dynamics, Patent Status, and Financial Trajectory

What is Technetium Tc 99m Mertiatide Kit used for?

Technetium Tc 99m mertiatide kit is a radioactive diagnostic product used after reconstitution with technetium-99m pertechnetate. It produces technetium Tc 99m mertiatide, also known as MAG3, for imaging renal perfusion, renal function, and urinary drainage.

The principal clinical uses are:

Dynamic renal scintigraphy
Diuretic renography
Evaluation of suspected urinary tract obstruction
Assessment of differential renal function
Imaging in patients with impaired renal function
Pediatric and adult urologic evaluation

Mertiatide is cleared primarily through tubular secretion. This makes it clinically useful when glomerular filtration is reduced, a setting in which technetium Tc 99m DTPA may provide less useful images. FDA labeling identifies renal imaging and renal function evaluation as the product’s principal indications.[1]

The product is generally supplied as a nonradioactive kit. A nuclear pharmacy or hospital radiopharmacy adds technetium-99m pertechnetate before administration. The short half-life of technetium-99m, approximately six hours, requires localized production, rapid distribution, and tight inventory management.[2]

Who markets Technetium Tc 99m Mertiatide Kit?

The principal commercial product has historically been TechneScan MAG3. The product was associated with Mallinckrodt’s nuclear imaging portfolio and is now commercially linked to Curium North America following the transfer of Mallinckrodt’s nuclear imaging business to Curium.[3]

Product	Active diagnostic agent	Original U.S. regulatory reference	Commercial association	Dosage form
TechneScan MAG3	Technetium Tc 99m mertiatide after reconstitution	NDA 019292	Curium North America; historically Mallinckrodt	Single-dose radiopharmaceutical kit
Generic or alternative MAG3 kits	Technetium Tc 99m mertiatide after reconstitution	Product-specific FDA filing	Limited commercial availability	Radiopharmaceutical kit

The U.S. market is concentrated because radiopharmaceutical manufacturing requires:

Specialized isotope-handling facilities
FDA-compliant sterile manufacturing
Validated kit chemistry
Radiological quality controls
Rapid delivery to hospitals and nuclear pharmacies
Access to technetium-99m generator or central-distribution networks

The product is not typically sold through ordinary retail pharmacy channels. Sales flow through hospital systems, radiology departments, nuclear pharmacies, radiopharmacy networks, and group purchasing organizations.

What is the FDA regulatory status of Technetium Tc 99m Mertiatide Kit?

Technetium Tc 99m mertiatide kit is an FDA-approved diagnostic radiopharmaceutical. The product is regulated as a drug and radioactive diagnostic agent, with manufacturing controls applying both to the kit and to the finished radiolabeled product.

The FDA-approved product requires reconstitution with sodium pertechnetate Tc 99m injection. The resulting preparation must meet radiochemical purity, sterility, and handling requirements before administration.[1]

The product’s regulatory profile is mature:

Regulatory factor	Status
FDA approval	Approved diagnostic radiopharmaceutical
Therapeutic indication	None; diagnostic renal imaging
Administration	Intravenous
Radioisotope	Technetium-99m
Product format	Nonradioactive kit requiring radiolabeling
Pediatric use	Established clinical use, subject to labeled and institutional protocols
Biosimilar pathway	Not applicable
505(b)(2) relevance	Limited for a conventional equivalent product
Generic competition	Possible through abbreviated or alternative regulatory pathways, but constrained by market size and manufacturing complexity

The product does not face biosimilar competition because biosimilar law applies to biological products, not small-molecule radiopharmaceutical kits. Competitive entry would more likely involve an abbreviated drug application, a drug-master-file-supported product, or another full drug application depending on the product’s formulation and regulatory differences.

What patents protect Technetium Tc 99m Mertiatide Kit?

The commercial patent estate for technetium Tc 99m mertiatide is effectively exhausted. The active ingredient and renal-imaging application date to the 1980s, and any early composition, kit, or use patents would ordinarily have expired decades ago.

A current commercial strategy does not depend on patent exclusivity. Protection is more likely to arise from operational barriers, manufacturing know-how, regulatory approvals, supply-chain relationships, and customer contracts.

IP category	Current commercial significance
Active ingredient patents	No meaningful remaining exclusivity expected
Kit formulation patents	Historical relevance; no material current barrier identified
Method-of-use patents	No meaningful current exclusivity expected for standard renal imaging
Manufacturing know-how	Potentially important, particularly for kit stability and radiochemical purity
Trademark protection	May protect product branding, not the underlying diagnostic agent
Regulatory exclusivity	No material current period expected
Trade secrets	Relevant to process controls, quality systems, and distribution

The FDA Orange Book remains the principal source for listed patents and regulatory exclusivity associated with approved drug products.[4] For this mature product, patent litigation risk is substantially lower than for recently approved small-molecule or biologic products.

When does Technetium Tc 99m Mertiatide lose exclusivity?

Technetium Tc 99m mertiatide has already lost meaningful market exclusivity. The product is not a current loss-of-exclusivity story. It is a mature diagnostic product whose commercial durability comes from utilization and supply reliability.

The relevant timeline is:

Period	Commercial development
1980s	Development and approval of MAG3-related renal imaging technology
Late 1980s onward	Clinical adoption for dynamic renal imaging and obstruction assessment
1990s-2000s	Patent and regulatory exclusivity periods expire
2010s	Market consolidates around specialized radiopharmaceutical suppliers
2020s	Demand remains tied to hospital nuclear medicine and technetium-99m supply

No meaningful current patent cliff is expected. A generic entrant could compete at any time if it satisfies FDA requirements and secures reliable isotope distribution. The practical issue is not legal exclusivity but whether expected sales justify the cost of sterile radiopharmaceutical manufacturing and nationwide or regional distribution.

Are there Paragraph IV challenges or patent lawsuits?

No major active Paragraph IV challenge or high-value patent litigation involving the core U.S. mertiatide product is central to the current market outlook.

Paragraph IV litigation is unlikely to be a major commercial variable because:

The product’s core patents are old.
There is no high-value remaining patent estate comparable to those surrounding branded oncology or autoimmune drugs.
Annual market revenue is not publicly disclosed at a level that would normally attract extensive patent litigation.
A potential entrant would face production, distribution, and reimbursement barriers even without patent litigation.

The key legal risks are more likely to involve product liability, quality-control events, supply contracts, regulatory compliance, and intellectual-property disputes over manufacturing processes rather than patent infringement claims over the active diagnostic agent.

How large is the market for Technetium Tc 99m Mertiatide Kit?

The product operates in a niche segment of the broader global nuclear-medicine market. Public market reports generally aggregate MAG3 within larger categories such as diagnostic radiopharmaceuticals, renal imaging agents, or technetium-99m products. Product-level global sales are not separately reported by Curium or other major suppliers.

Demand is supported by:

A large installed base of nuclear-medicine departments
Continued use in pediatric urology and adult obstruction studies
Clinical preference for MAG3 in reduced renal function
The need for functional, rather than purely anatomical, renal assessment
Recurring hospital and radiopharmacy purchases

Demand is constrained by:

Competition from ultrasound, CT urography, MR urography, and other imaging methods
Declining or uneven nuclear-medicine procedure volumes in some markets
Limited availability of trained nuclear-medicine personnel
Short product shelf life after radiolabeling
Technetium-99m supply interruptions
Hospital cost controls and centralized purchasing

The product has relatively low volume compared with major contrast agents or therapeutic radiopharmaceuticals. Its value per dose is higher than a conventional generic tablet but its total addressable market is much smaller.

What competitors challenge Technetium Tc 99m Mertiatide Kit?

The closest product competitors are other renal imaging agents rather than direct therapeutic substitutes.

Competitor	Primary role	Competitive position
Technetium Tc 99m DTPA	Glomerular filtration and renal perfusion imaging	Lower cost or broader availability; less favorable in impaired renal function
Technetium Tc 99m DMSA	Cortical renal imaging	Used for cortical defects and scarring, not a direct MAG3 replacement
Iodine-123 hippuran, where available	Renal functional imaging	Historical or geographically limited alternative
Ultrasound	Structural and obstruction assessment	No ionizing radiation; does not provide equivalent functional data
CT urography	Anatomical urinary tract imaging	Strong anatomical detail; radiation and contrast considerations
MR urography	Anatomical and functional imaging	Higher cost and lower availability in some settings
Diuretic renography using alternative agents	Functional obstruction assessment	Directly competes when an alternative radiotracer is available

MAG3 has a defensible clinical position when the physician needs quantitative or dynamic renal drainage data and the patient has reduced renal function. That clinical positioning limits substitution, although it does not eliminate it.

What is the reimbursement and pricing outlook?

In the United States, technetium Tc 99m mertiatide is reimbursed through radiology and nuclear-medicine payment structures rather than a conventional pharmacy benefit. Medicare’s HCPCS code A9539 covers technetium Tc 99m mertiatide, diagnostic, per study dose up to the applicable millicurie limit.[5]

Pricing depends on:

Hospital outpatient payment rates
Physician-office or independent imaging-center contracts
Wholesale and nuclear-pharmacy purchasing arrangements
Dose size and wastage
Delivery distance and timing
Technetium-99m generator costs
Regional competition among radiopharmacies
Hospital group purchasing agreements

The principal pricing risk is reimbursement compression. Because the product is a mature diagnostic agent, price increases generally require justification based on isotope costs, labor, compliance, sterile manufacturing, or distribution. Hospitals can resist increases if alternative imaging methods are available or if suppliers compete in the same geography.

The principal margin opportunity is operational efficiency. Suppliers that reduce failed batches, minimize dose wastage, maintain dependable delivery, and optimize generator utilization can preserve margins without relying on patent pricing.

What is the financial trajectory for Technetium Tc 99m Mertiatide Kit?

The product’s financial trajectory is likely mature and stable rather than high-growth. Public financial statements do not generally disclose standalone revenue, gross margin, or operating profit for MAG3. Curium is privately held, and historical Mallinckrodt reporting grouped nuclear imaging products within broader pharmaceutical segments.[3]

A reasonable commercial profile is:

Financial driver	Directional effect
Nuclear-medicine procedure volume	Determines baseline demand
MAG3 clinical preference in renal impairment	Supports utilization
Technetium-99m availability	Can create abrupt volume and revenue volatility
Product price	Mature pricing with limited exclusivity premium
Manufacturing yield	Direct effect on gross margin
Radiopharmacy distribution density	Direct effect on delivery cost and service quality
Alternative imaging	Long-term substitution pressure
Hospital consolidation	Buyer power can reduce net pricing
Regulatory compliance	Fixed-cost burden favors established suppliers

Revenue is likely to be resilient in established nuclear-medicine markets but exposed to episodic supply disruptions. Growth is more likely to come from geographic expansion, hospital conversion, improved distribution, or broader nuclear-imaging utilization than from price increases.

The highest-value commercial asset is not the molecule. It is dependable access to isotope supply, validated kit production, and time-critical delivery.

What manufacturing and supply barriers affect the market?

Technetium-99m supply is linked to molybdenum-99 production and generator networks. The global supply chain includes reactor production, processing, generator manufacture, shipment, radiopharmacy preparation, and final hospital administration. Interruptions at any point can affect MAG3 availability.[2,6]

Manufacturing barriers include:

Sterile kit production
Radiochemical purity testing
Stability validation
Compatibility with sodium pertechnetate from different sources
Short radiolabeled product shelf life
Radioactive-material transportation requirements
Specialized facility licensing
Trained personnel
Batch release and quality-control timing

These barriers create a stronger practical moat than patent law. They also increase fixed costs and make small-scale entry unattractive.

How does Technetium Tc 99m Mertiatide compare with newer radiopharmaceuticals?

MAG3 is a low-growth diagnostic product, while newer radiopharmaceutical categories, particularly targeted radioligand therapies and positron-emission tomography agents, have higher strategic value and faster market expansion. Those newer products command more investment because they have larger revenue opportunities, patent protection, or therapeutic applications.

MAG3 has different advantages:

Established clinical protocols
Familiarity among nuclear-medicine physicians
Broad hospital infrastructure
Relatively simple kit-based preparation
No dependence on a therapeutic indication
Recurring diagnostic utilization

Its disadvantages are the absence of meaningful exclusivity, limited pricing power, and exposure to declining nuclear-medicine infrastructure in some regions.

What generic launch risks exist?

A generic or alternative mertiatide kit could launch without facing a major patent barrier, but commercial success would remain uncertain.

The principal launch risks are:

Limited market size
Need for reliable technetium-99m access
Requirement for rapid distribution
Customer preference for established radiopharmacy suppliers
Low tolerance for delivery failures
Regional rather than national purchasing economics
Difficulty achieving adequate manufacturing utilization
Reimbursement rates that limit price differentiation

A new entrant would need to compete on supply reliability, geographic coverage, hospital contracts, and service quality. A low-price strategy alone would be insufficient if the supplier could not deliver radiolabeled doses within the required operating window.

What licensing deals affect Technetium Tc 99m Mertiatide?

No major current licensing transaction is publicly associated with the core MAG3 active ingredient. The commercial history has been shaped more by portfolio transfers and business acquisitions than by new molecule licensing.

The relevant transaction pattern is the transfer of nuclear-imaging products from larger pharmaceutical companies to specialized radiopharmaceutical operators. Such transactions can preserve product availability while moving mature assets to companies with more focused manufacturing and distribution infrastructure.[3]

Future licensing value would likely relate to:

Regional distribution rights
Radiopharmacy supply agreements
Kit manufacturing rights
Private-label hospital contracts
Access to technetium-99m generator capacity
Co-marketing arrangements

How strong is the patent estate for Technetium Tc 99m Mertiatide Kit?

The patent estate is weak as a current exclusivity asset but durable as a commercial product platform.

Strength category	Assessment
Composition-of-matter protection	Exhausted
Method-of-use protection	Exhausted or commercially immaterial
Formulation protection	Limited current value
Regulatory exclusivity	No meaningful current protection expected
Manufacturing know-how	Moderate practical value
Distribution network	High practical value
Brand recognition	Moderate value
Switching barriers	Moderate because of workflow and reliability
Litigation exposure	Low relative to newer branded drugs

Investors should evaluate the product as an operationally protected mature diagnostic, not as a patent-protected pharmaceutical.

Key Takeaways

Technetium Tc 99m mertiatide kit is an FDA-approved renal-imaging radiopharmaceutical commonly associated with TechneScan MAG3.
The product is mature and effectively off patent.
No current Paragraph IV or major patent-litigation risk is central to the market outlook.
Biosimilar competition does not apply.
The main competitors are Tc 99m DTPA, Tc 99m DMSA, ultrasound, CT urography, and MR urography.
Standalone revenue and profitability are not publicly disclosed.
Financial performance depends on procedure volumes, isotope supply, radiopharmacy distribution, reimbursement, and manufacturing yield.
The strongest commercial barriers are sterile production, radioactive-material logistics, quality controls, and dependable delivery.
Growth prospects are limited but recurring demand supports a stable mature-product profile.
Generic entry is legally feasible but commercially difficult because the market is specialized and operationally demanding.

FAQs

Is Technetium Tc 99m Mertiatide the same as MAG3?

Yes. MAG3 refers to mertiatide, the renal imaging compound that is labeled with technetium-99m before administration.

Does Technetium Tc 99m Mertiatide have orphan-drug exclusivity?

No material current orphan-drug exclusivity is associated with the standard renal-imaging product.

Can hospitals substitute Tc 99m DTPA for MAG3?

Sometimes, but the agents are not clinically identical. MAG3 is often preferred when renal function is reduced or when efficient tubular extraction and urinary drainage imaging are required.

Is Curium the only supplier of Technetium Tc 99m Mertiatide in the United States?

Curium is the principal commercial supplier associated with TechneScan MAG3, but product availability and alternative sourcing can vary by region, regulatory status, and radiopharmacy contracts.

What is the biggest investment risk for a MAG3 supplier?

The largest risks are technetium-99m supply disruption, reimbursement pressure, declining nuclear-medicine volumes, manufacturing failures, and hospital purchasing consolidation.

References

U.S. Food and Drug Administration. (n.d.). TechneScan MAG3 prescribing information. FDA Drugs@FDA.
International Atomic Energy Agency. (2023). Molybdenum-99/technetium-99m production and supply. IAEA.
Curium Pharma. (n.d.). Nuclear medicine products and company information. Curium Pharma.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
Centers for Medicare & Medicaid Services. (2024). HCPCS code A9539: Technetium Tc-99m mertiatide, diagnostic, per study dose. CMS.
National Academies of Sciences, Engineering, and Medicine. (2009). Molybdenum-99 for medical imaging. National Academies Press.

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
DailyMed Link:	TECHNETIUM TC99M MERTIATIDE KIT at DailyMed

TECHNETIUM TC99M MERTIATIDE KIT Drug Patent Profile

Which patents cover Technetium Tc99m Mertiatide Kit, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for TECHNETIUM TC99M MERTIATIDE KIT

US Patents and Regulatory Information for TECHNETIUM TC99M MERTIATIDE KIT